Medical Reform Negative "domestic Demand" Engine Pharmaceutical Companies To The College Entrance

As "domestic demand" engine strong start, theforcing enterprises to pursue flexible and innovative
medical and health sector is bound to be a crucial onebusiness model. "safety is always the Eastern
hot market. Against this background, new Medicalpharmaceutical industry managing partner, said Li
Reform Program role to play Pharmaceutical IndustryYongguang.
Might face more competition and depth adjustment.Ernst & Young has 15 operating in China on the
11 5, the State Council executive meeting, study andglobal leader in system Pharmaceutical companies 40
plan to further expand domestic demand to promotesenior industry executives surveyed, the results
fast and steady economic growth of 10 measures toshow that, despite the global financial crisis on China's
accelerate the development of health care rankedreal economy and the consumer market is still difficult
among the requirements, and infrastructureto accurately determine the extent, but the next
construction, affordable housing and financialfew years, China will remain the most important
industries together constitute the mainstay of China'spharmaceutical market growth 1, and China's current
economic stability and industry. Directly related withmedical needs are increasing.
the 10 measures, the next two years the state willAlthough the macro-direction is clear, but in the midst
add 4 trillion yuan investment, which is equivalent toof which the future prospects of pharmaceutical
total fixed asset investment in 2007 to 29.2%. Thecompanies still grew by nearly half and half. At the
context of medical reform Pharmaceutical marketrecent situation of Chinese medicine for 30 years will
Seems to be of interest.be an interview process, a number of pharmaceutical
Frank Gong, managing director of Morgan Chase hascompanies, said its 2008 profits had been affected
talked about China's steady economic growth in theby macroeconomic impact of lower than expected.
policy premise that the Chinese government toTo produce anti-tumor drugs such as cardiovascular
smooth the economy can invest in infrastructure,disease mainly of large integrated pharmaceutical
strategic policy support and financial subsidies to docompanies with the Jubilee Qilu Pharmaceutical Vice
something. The strategic policies that includeChairman Ma introduced to the Shanghai Securities
education, health care and social security.News, the first 10 months of this year, the company
"The Chinese government investment in recent yearsexports pharmaceutical and contract prices dropped
to strengthen health and improve the health careabout 20% of sales . Although highly promising
system, efforts to help speed up the release of theforward market, but by the impact of uncertainty,
pharmaceutical industry's domestic demand, while theexpected next year group sales have been down.
recently released new medical reform and otherMore of a Traditional Chinese medicine Company
measures to deepen the medical and health systemexecutives said that some main Chinese caterpillar
will further consolidate this a trend. "Xinhua Financefungus, etc. Traditional Chinese medicine Nourishment
entitled" Prospects for China's pharmaceuticalof the corporate earnings have been down more
industry, the credit, "the report said. In addition,than 40%.
because investment in medical and health servicesWith medical reform plan is still in the process of
can not only pull the output value of pharmaceuticalintense debate, including essential drugs system and
industry, but also to protect family health care costsother new regulations will affect pharmaceutical
by reducing the boost consumer confidence in othercompanies in the extent to which the structure and
sectors, thus stimulating social and economic capacitydevelopment are still variable. "China is a drug support
may be doubled overall, with the data, said per 100system of medicine evolved over the years, and
million yuan on medical protection of the financialinvolve the interests of deep-rooted party,
investment community can pull the total amountcompletely change the need for state financial
spent one billion yuan.investment is too large, but once the investment is
"Large global pharmaceutical company is expanding itsnot in place or the wrong direction, health care
operations in the Chinese market, which showsreform would be counterproductive." A medicine
China's increasing purchasing power and coverage ofexperts said. Among them, the system may lead to
broader health care system has brought an importantessential drugs essential drugs on the market battle
opportunity. But at the same time, a number offor qualification one of the greatest concern.
business opportunities in China the complexity of the